Nanomedicine: Nanotechnology, Biology and Medicine
Volume 2, Issue 2 , Pages 95-102 , June 2006

Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles

Received 22 February 2006 ,Accepted 7 April 2006.

References 

  1. Langer R. Drug delivery and targeting. Nature. 1998;392:5–10
  2. Kiser PF, Wilson G, Needham D. A synthetic mimic of the secretory granule for drug delivery. Nature. 1998;394:459–462
  3. Ong S, Liu H, Qiu X, Bhat G, Pidgeon C. Membrane partition coefficients chromatographically measured using immobilized artificial membrane surfaces. Anal Chem. 1995;67:755–762
  4. Rogers JA, Choi YW. The liposome partitioning system for correlating biological activities of imidazolidine derivatives. Pharm Res. 1993;10:913–917
  5. Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science. 2003;300:615–618
  6. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818–1822
  7. Meier W. Polymer nanocapsules. Chem Soc Rev. 2000;29:295–303
  8. Tabata M, Kondo M, Haruta Y, Seon BK. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using 125I-labeled anti-endoglin monoclonal antibodies. Int J Cancer. 1999;82:737–742
  9. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377–380
  10. Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol Rev. 1999;170:151–172
  11. Lechmann M, Liang TJ. Vaccine development for hepatitis C. Semin Liver Dis. 2000;20:211–226
  12. Paul WE. Can the immune response control HIV infection?. Cell. 1995;82:177–182
  13. Gahery-Segard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, et al. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol. 2000;74:1694–1703
  14. Gras-Masse H. Single-chain lipopeptide vaccines for the induction of virus-specific cytotoxic T cell responses in randomly selected populations. Mol Immunol. 2001;38:423–431
  15. Hoffman SL, Subramanian GM, Collins FH, Venter JC. Plasmodium, human and Anopheles genomics and malaria. Nature. 2002;415:702–709
  16. Wang J, Zganiacz A, Xing Z. Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation. Vaccine. 2002;20:2887–2898
  17. Hayman WA, Toth I, Flinn N, Scanlon M, Good MF. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Immunol Cell Biol. 2002;80:178–187
  18. Nesburn AB, Burke RL, Ghiasi H, Slanina SM, Wechsler SL. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Virology. 1998;252:200–209
  19. Wareing MD, Tannock GA. Influenza update: vaccine development and clinical trials. Curr Opin Pulm Med. 2002;8:209–213
  20. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. J Natl Cancer Inst. 2002;94:805–818
  21. Van Regenmortel MH. Antigenicity and immunogenicity of synthetic peptides. Biologicals. 2001;29:209–213
  22. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines—yesterday, today, and tomorrow. Lancet Infect Dis. 2002;2:425–431
  23. Johnson JE, Reddy VS. Biggest virus molecular structure yet!. Nat Struct Biol. 1998;5:849–854
  24. Padilla JE, Colovos C, Yeates TO. Nanohedra: using symmetry to design self assembling protein cages, layers, crystals, and filaments. Proc Natl Acad Sci USA. 2001;98:2217–2221
  25. Burkhard P, Strelkov SV, Stetefeld J. Coiled coils: a highly versatile protein folding motif. Trends Cell Biol. 2001;11:82–88
  26. Lupas A. Coiled coils: new structures and new functions. Trends Biochem Sci. 1996;21:375–382
  27. O'Shea EK, Klemm JD, Kim PS, Alber T. X-ray structure of the GCN4 leucine zipper, a two-stranded, parallel coiled coil. Science. 1991;254:539–544
  28. Tao Y, Strelkov SV, Mesyanzhinov VV, Rossmann MG. Structure of bacteriophage T4 fibritin: a segmented coiled coil and the role of the C-terminal domain. Structure. 1997;5:789–798
  29. Stetefeld J, Jenny M, Schulthess T, Landwehr R, Engel J, Kammerer RA. Crystal structure of a naturally occurring parallel right-handed coiled coil tetramer. Nat Struct Biol. 2000;7:772–776
  30. Malashkevich VN, Kammerer RA, Efimov VP, Schulthess T, Engel J. The crystal structure of a five-stranded coiled coil in COMP: a prototype ion channel?. [see comments] Science. 1996;274:761–765
  31. Sanner MF, Stolz M, Burkhard P, Kong XP, Min G, et al. Visualizing nature at work from the nano to the macro scale. Nanobiotechnology. 2005;1:7–22
  32. Burkhard P, Meier M, Lustig A. Design of a minimal protein oligomerization domain by a structural approach. Protein Sci. 2000;9:2294–2301
  33. Burkhard P, Kammerer RA, Steinmetz MO, Bourenkov GP, Aebi U. The coiled-coil trigger site of the rod domain of cortexillin I unveils a distinct network of interhelical and intrahelical salt bridges. Structure Fold Des. 2000;8:223–230
  34. Burkhard P, Ivaninskii S, Lustig A. Improving coiled-coil stability by optimizing ionic interactions. J Mol Biol. 2002;318:901–910
  35. Guo Y, Kammerer RA, Engel J. The unusually stable coiled-coil domain of COMP exhibits cold and heat denaturation in 4-6 M guanidinium chloride [in process citation]. Biophys Chem. 2000;85:179–186
  36. Fehr T, Skrastina D, Pumpens P, Zinkernagel RM. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc Natl Acad Sci USA. 1998;95:9477–9481
  37. Hunter RL. Overview of vaccine adjuvants: present and future. Vaccine. 2002;20(Suppl 3):S7–S12

☆ No financial conflict of interest was reported by the authors of this paper.

☆☆ This research was supported by the M.E. Müller Foundation and the NCCR Nanoscale Science (SNF). The authors would like to thank J. Engel and W. Meier for critical reading of the manuscript.

PII: S1549-9634(06)00047-5

doi: 10.1016/j.nano.2006.04.007

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 2, Issue 2 , Pages 95-102 , June 2006

Article Tools

* Image Usage & Resolution